GOVX - GeoVax Labs, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

GOVX

GEOVAX LABS, INC.

NASDAQ

$0.72

▲ UP 0.56% (0.00)

KEY STATISTICS

Market Cap$5.31 M

52w High$19.20

52w Low$0.59

Dividend Yield—

Frequency—

P/E-0.06

Volume704.23K

Shares Out.7.37M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

David Alan Dodd

COMPENSATION 2026

Salary$309,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$5,515

Total$652,012

ABOUT

SECTOR

Healthcare

WENT PUBLIC

September 25, 2020

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$100.00

Target Low$100.00

Target Median$100.00

Target Consensus$100.00

UPCOMING EARNINGS

DateNov 12, 2026

DayThursday

Rev. Est.—

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2026-01-12	Reverse	1:25
2024-01-31	Reverse	1:15
2020-09-25	Reverse	1:20
2020-02-19	Reverse	1:2000
2020-01-24	Reverse	1:2000
2019-05-02	Reverse	1:500
2010-04-28	Reverse	1:50

PRICE

$0.72 ▲ UP 0.56% (+$0.00)

OVERLAYS

About GeoVax Labs, Inc.

https://www.geovax.com ↗

GeoVax Labs, Inc. is a biotech company developing vaccines and immunotherapies for infectious diseases and cancers using a modified vaccinia Ankara platform, with partnerships including NIH, CDC, DoD, and universities.

INDUSTRY

Biotechnology

A PRODUCT GEOVAX LABS, INC. IS KNOWN FOR

Gedeptin®

Gedeptin® is a clinical-stage gene-directed enzyme prodrug therapy for solid tumors, primarily targeting head and neck cancers, with completed Phase 1/2 trials and plans for Phase 2 combined with immune checkpoint inhibitors.